Treatment strategy for metastatic breast cancer with estrogen receptor-positive tumor.

about

Fibroblast growth factor receptor-1 protein expression is associated with prognosis in estrogen receptor-positive/human epidermal growth factor receptor-2-negative primary breast cancer.The effect of royal jelly on the growth of breast cancer in mice.

P2860

Q36801189-7B215F39-3C17-4B03-8338-DF23D9CB85F0 Q49839312-F3CFFB87-96FC-47CB-A2E7-558DB650CE5B

P2860

Treatment strategy for metastatic breast cancer with estrogen receptor-positive tumor.

Item

http://www.wikidata.org/entity/Q38349784

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Treatment strategy for metastatic breast cancer with estrogen receptor-positive tumor.

@en

type

Item

label

Treatment strategy for metastatic breast cancer with estrogen receptor-positive tumor.

@en

prefLabel

Treatment strategy for metastatic breast cancer with estrogen receptor-positive tumor.

@en

P1476

Treatment strategy for metastatic breast cancer with estrogen receptor-positive tumor.

@en

P2093

Hirotaka Iwase

http://www.w3.org/2001/XMLSchema#string

P2860

Survival of metastatic breast carcinoma patients over a 20-year period: a retrospective analysis based on individual patient data from six consecutive studies.

Is breast cancer survival improving?

Palbociclib (PD 0332991) : targeting the cell cycle machinery in breast cancer.

Optimizing the treatment of metastatic breast cancer.

Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: a phase 2 randomized study

Clinical challenges in the molecular characterization of circulating tumour cells in breast cancer.

Ethinylestradiol is beneficial for postmenopausal patients with heavily pre-treated metastatic breast cancer after prior aromatase inhibitor treatment: a prospective study.

Current topics and perspectives on the use of aromatase inhibitors in the treatment of breast cancer.

Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis.

The role of radiological-pathological correlation in diagnosing early breast cancer: the pathologist's perspective.

P2888

s10147-015-0795-6

P304

249-252

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10147-015-0795-6

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-02-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

272193275

http://www.w3.org/2001/XMLSchema#string

P698

25666484

http://www.w3.org/2001/XMLSchema#string

Treatment strategy for metastatic breast cancer with estrogen receptor-positive tumor.

about

P2860

P2860

Treatment strategy for metastatic breast cancer with estrogen receptor-positive tumor.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P5875

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P5875

P698